

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
<i>Escherichia</i>	Not applicable	<i>In vitro</i> and mouse studies identified nine antigens of pathogenic <i>E. coli</i> that could be used to develop a prophylactic vaccine. Genome studies of pathogenic extraintestinal <i>E. coli</i> (ExPEC) strains identified genomic regions that were unique to pathogenic strains of the bacteria. In mice, nine antigens derived from the regions prevented bacterial infection and death compared with no treatment. Next steps could include combining the antigens with adjuvants to create a prototype vaccine for testing in animal models of <i>E. coli</i> infection.	Patent and licensing status undisclosed	Moriel, D. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online May 3, 2010; doi:10.1073/pnas.0915077107 Contact: Rino Rappuoli, Novartis Vaccines, Siena, Italy e-mail: rino.rappuoli@novartis.com
<p>SciBX 3(19); doi:10.1038/scibx.2010.587 Published online May 13, 2010</p>				